ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® in combination with ADT prolonged median overall survival by 14 months and decreased the risk of death by 22 percent.1 Median OS was significantly longer, with 73.9 months for patients receiving treatment with ERLEADA® in combination with ADT compared to 59.9 months with patients receiving placebo in combination with ADT [HR=0.78; p=0.0161 (to reach statistical significance, a p-value of p30% body surface area [BSA]) were reported with ERLEADA® treatment (6%) versus placebo (0.5%).The onset of rash occurred at a median of 83 days. Rash resolved in 78% of patients within a median of 78 days from onset of rash. Rash was commonly managed with oral antihistamines, topical corticosteroids, and 19% of patients received systemic corticosteroids. Dose reduction or dose interruption occurred in 14% and 28% of patients, respectively. Of the patients who had dos...
Publication date: Available online 10 July 2020Source: Revista Clínica Española (English Edition)Author(s): J.J. Hijona Elósegui, A.L. Carballo García, A.C. Fernández Risquez, M. Bermúdez Quintana, J.F. Expósito Montes
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Roderick C.N. van den Bergh, Olivier Rouvière, Theodorus van der Kwast, Erik Briers, Thomas Van den Broeck, Philip Cornford, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Nikolaos Grivas, Jeremy Grummet, Thomas B. Lam, Michael Lardas, Matthew Liew, Lisa Moris, Malcolm D. Mason, Nicolas Mottet, Daniela E. Oprea-Lager
Do not Rx oral steroids for back pain.
Publication date: Available online 11 July 2020Source: European Journal of Surgical OncologyAuthor(s): Xin Chen, Xingyu Feng, Muqing Wang, Xueqing Yao
Hey Everyone! I just graduated and I made the decision to pursue veterinary school. In this lost I am looking to get a little direction on the courses that I still should take. I have taken the full biology, general chemistry, organic chemistry, and physics sequences. Additional I have taken a calculus course and a biochemistry course. I have taken a psychology statistics course, but I will probably end up taking a statistics course through the math department. Other than these courses... Unsure of my next steps
Conclusions: Negative ICS beliefs are associated with higher number of oral steroid courses. The association between CAM endorsement and asthma control is varied, but mostly in favor of improved control. Financial difficulties may make CAM use more likely. PMID: 32646322 [PubMed - as supplied by publisher]
Authors: Josiassen J, Frydland M, Holmvang L, Kristian Lerche Helgestad O, Okkels Jensen L, Goetze JP, Eifer Moeller J, Hassager C Abstract PURPOSE: To validate the IABP-SHOCK II risk score in a Danish cohort and assess the association between the risk score and admission concentration of biomarkers reflecting neurohormonal- (Copeptin, Pro-atrial natriuretic peptide (proANP), Mid-regional pro-adrenomedullin (MRproADM)) and inflammatory (ST2) activation in patients with CS complicating ST segment elevation myocardial infarction (STEMI). METHODS: A total of 137 consecutive patients admitted with STEMI and CS at t...
Publication date: Available online 10 July 2020Source: Respiratory Physiology &NeurobiologyAuthor(s): Paula Mattos-Silva, Nathane Santanna Felix, Pedro Leme Silva, Chiara Robba, Denise Battaglini, Paolo Pelosi, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz
Publication date: Available online 10 July 2020Source: Pathology - Research and PracticeAuthor(s): Yiyang Bai, Jia Hou, Xiao Wang, Luying Geng, Xiaohui Jia, Luochengling Xiang, Kejun Nan
CONCLUSIONS: HFNO provides a hands-free induction of general anaesthesia and yields adequate preoxygenation and peroxygenation, with a significant improvement in the quality of care. PMID: 32643359 [PubMed - as supplied by publisher]
More News: Allergy & Immunology | Anemia | Brain | Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemistry | Chemotherapy | Clinical Trials | Congestive Heart Failure | Corticosteroid Therapy | Diabetes | Endocrinology | Epilepsy | Health Management | Heart | Heart Attack | Heart Disease | Heart Failure | Hematology | Hormonal Therapy | Hormones | Hypertension | Hypothyroidism | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Oral Cancer | Organic | Orthopaedics | Pain | Pain Management | PET Scan | Pharmaceuticals | Politics | Pregnancy | Pregnancy and Breast Cancer | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Radiation Therapy | Radiography | Science | Statistics | Study | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines | Warnings